Reported Earlier, Zenas Biopharm Announced The Presentation Of Additional Positive Data From The Phase 3 Indigo Trial Evaluating Obexelimab In Immunoglobulin G4-related Disease (Igg4-rd) At The European Alliance Of Associations For Rheumatology (Eular) 2026 Congress In London, England

뉴스 본문을 불러오고 있어요.

Reported Earlier, Zenas Biopharm Announced The Presentation Of Additional Positive Data From The Phase 3 Indigo Trial Evaluating Obexelimab In Immunoglobulin G4-related Disease (Igg4-rd) At The European Alliance Of Associations For Rheumatology (Eular) 2026 Congress In London, England | 웨이프 WAPE

Reported Earlier, Zenas Biopharm Announced The Presentation Of Additional Positive Data From The Phase 3 Indigo Trial Evaluating Obexelimab In Immunoglobulin G4-related Disease (Igg4-rd) At The European Alliance Of Associations For Rheumatology (Eular) 2026 Congress In London, England

기사 요약

관련 종목

댓글 —